The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Official Title: A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Study ID: NCT03446040
Brief Summary: The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 0004, Los Angeles, California, United States
Local Institution - 0006, Los Angeles, California, United States
Local Institution - 0007, Aurora, Colorado, United States
University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
Local Institution - 0018, Ann Arbor, Michigan, United States
Local Institution - 0010, Grand Rapids, Michigan, United States
Local Institution - 0012, Lebanon, New Hampshire, United States
Local Institution - 0016, Cincinnati, Ohio, United States
Local Institution - 0005, Pittsburgh, Pennsylvania, United States
Local Institution - 0002, Germantown, Tennessee, United States
Local Institution - 0013, Westmead, New South Wales, Australia
Local Institution - 0015, Melbourne, Victoria, Australia
Local Institution - 0014, Edmonton, Alberta, Canada
Local Institution - 0019, Vancouver, British Columbia, Canada
Local Institution - 0009, Kobe-shi, Hyogo, Japan
Local Institution - 0008, Chuo-ku, Tokyo, Japan
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR